BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 26657418)

  • 1. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
    Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
    Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of class I but not class IIb histone deacetylases exerts cardiac protection from ischemia reperfusion.
    Aune SE; Herr DJ; Mani SK; Menick DR
    J Mol Cell Cardiol; 2014 Jul; 72():138-45. PubMed ID: 24632412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness.
    Leyk J; Daly C; Janssen-Bienhold U; Kennedy BN; Richter-Landsberg C
    Cell Death Dis; 2017 Aug; 8(8):e3028. PubMed ID: 29048427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects.
    Vishwakarma S; Iyer LR; Muley M; Singh PK; Shastry A; Saxena A; Kulathingal J; Vijaykanth G; Raghul J; Rajesh N; Rathinasamy S; Kachhadia V; Kilambi N; Rajgopal S; Balasubramanian G; Narayanan S
    Int Immunopharmacol; 2013 May; 16(1):72-8. PubMed ID: 23541634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MeCP2 deficiency is associated with reduced levels of tubulin acetylation and can be restored using HDAC6 inhibitors.
    Gold WA; Lacina TA; Cantrill LC; Christodoulou J
    J Mol Med (Berl); 2015 Jan; 93(1):63-72. PubMed ID: 25209898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model.
    Li Y; Zhao T; Liu B; Halaweish I; Mazitschek R; Duan X; Alam HB
    J Trauma Acute Care Surg; 2015 Feb; 78(2):378-85. PubMed ID: 25757125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury.
    Jian W; Wei X; Chen L; Wang Z; Sun Y; Zhu S; Lou H; Yan S; Li X; Zhou J; Zhang B
    Neurosci Lett; 2017 Sep; 658():114-120. PubMed ID: 28823893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective HDAC6 inhibition prevents TNF-α-induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema.
    Yu J; Ma Z; Shetty S; Ma M; Fu J
    Am J Physiol Lung Cell Mol Physiol; 2016 Jul; 311(1):L39-47. PubMed ID: 27190059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes.
    Choi SY; Ryu Y; Kee HJ; Cho SN; Kim GR; Cho JY; Kim HS; Kim IK; Jeong MH
    Vascul Pharmacol; 2015 Sep; 72():130-40. PubMed ID: 25921924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone Deacetylase Inhibitors Promote Mitochondrial Reactive Oxygen Species Production and Bacterial Clearance by Human Macrophages.
    Ariffin JK; das Gupta K; Kapetanovic R; Iyer A; Reid RC; Fairlie DP; Sweet MJ
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1521-9. PubMed ID: 26711769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells.
    Asthana J; Kapoor S; Mohan R; Panda D
    J Biol Chem; 2013 Aug; 288(31):22516-26. PubMed ID: 23798680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.
    Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A
    Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
    Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
    J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
    Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
    PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation.
    Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY
    Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
    Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
    Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of novel N-benzyltriazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
    Kong SJ; Nam G; Boggu PR; Park GM; Kang JE; Park HJ; Jung YH
    Bioorg Med Chem; 2023 Feb; 79():117154. PubMed ID: 36645952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance.
    Leyk J; Goldbaum O; Noack M; Richter-Landsberg C
    J Mol Neurosci; 2015 Apr; 55(4):1031-46. PubMed ID: 25434725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.